Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy.
Chiriaco C, Donini C, Cortese M, Ughetto S, Modica C, Martinelli I, Proment A, Vitali L, Fontani L, Casucci M, Comoglio PM, Giordano S, Sangiolo D, Leuci V, Vigna E.
Chiriaco C, et al. Among authors: giordano s.
J Exp Clin Cancer Res. 2022 Oct 21;41(1):309. doi: 10.1186/s13046-022-02479-y.
J Exp Clin Cancer Res. 2022.
PMID: 36271379
Free PMC article.